Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-330-6 | CAS number: 462-95-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Point 8.4.1: new test performed according to OECD TG 471 with ethylal with negative results.
Point 8.4.2: new test performed according to OECD TG 487 with ethylal with negative results.
Point 8.4.3: new test performed according to OECD TG 490 with ethylal with negative results.
8.4.1.
Two Ames tests are available.
Report of Seifried et al. (2006) is a published compilation of mutagenicity test results performed on more than 400 substances including Diethoxymethane. This report is considered as not reliable based on absence of information on substance purity, documentation and raw data. Under the experimental conditions, the test item Diethoxymethane does not show mutagenic activity in the bacterial reverse mutation test on Salmonella typhimurium.
This absence of concern is supported by recent key study (considered as reliable without restriction) fully documented and performed according to OECD 471 and GLP. The test item Diethoxymethane did not induce an increase in the frequency of revertant colonies at any of the dose levels used either with or without metabolic activation (S9-mix). Under the conditions of this test Diethoxymethane was concluded as non-mutagenic.
8.4.2
A recent key test (in vitro micronucleus study) has been performed according to OECD 487 and GLP. Under the conditions of this study, the test item, Diethoxymethane, was considered to be non-clastogenic and nonaneugenic to human lymphocytes in vitro.
8.4.3
Report of Seifried et al. (2006) is a published compilation of mutagenicity test results performed on more than 400 substances including Diethoxymethane. This report is considered as not reliable based on absence of information on substance purity, documentation and raw data. Under the experimental conditions, the test item Diethoxymethane is negative without metabolic activation and positive with metabolic activation in mouse lymphoma assay.
A recent key test (in vitro mammalian cell gene mutation test using TK gene study) has been performed according to OECD 490 and GLP. Under the conditions of this study, the test item, Diethoxymethane, did not induce any increases in the mutant frequency at the TK +/- locus in L5178Y cells that exceeded the Global Evaluation Factor (GEF) of 126 x 10-6, consequently it is considered to be non-mutagenic in this assay.
Outcome of the report of Seifried et al. (2006) is therefore waived and superseded by outcome of test performed according to current guideline and GLP.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Experimental start date 09 March 2018 Experimental completion date 29 March 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- Identification: Diethoxymethane
Synonym: Ethylal
CAS Number: 462-95-3
Physical State/Appearance: Clear colourless liquid
Storage Conditions: Approximately 4 °C, in the dark, under nitrogen
No correction for purity was required. - Target gene:
- Histidine locus in the Salmonella strains and tryptophan locus in E.coli.
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and E. coli WP2
- Metabolic activation:
- with and without
- Metabolic activation system:
- rat liver homogenate metabolizing system (10% liver S9 in standard co-factors)
- Test concentrations with justification for top dose:
- Experiment 1 – Plate Incorporation Method
The maximum concentration was 5000 μg/plate (the OECD TG 471 maximum recommended dose level).
Eight concentrations of the test item (1.5, 5, 15, 50, 150, 500, 1500 and 5000 μg/plate) were assayed.
Experiment 2 – Pre-Incubation Method
The dose range used for Experiment 2 was determined by the results of Experiment 1 and was 15, 50, 150, 500, 1500 and 5000 μg/plate. - Vehicle / solvent:
- The test item was fully miscible in sterile distilled water at 50 mg/mL in solubility checks performed in-house. Sterile distilled water was therefore selected as the vehicle.
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 2 μg/plate for WP2uvrA, 3 μg/plate for TA100, 5 μg/plate for TA1535
- Positive control substance:
- N-ethyl-N-nitro-N-nitrosoguanidine
- Remarks:
- absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 80 μg/plate for TA1537
- Positive control substance:
- 9-aminoacridine
- Remarks:
- absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.2 μg/plate for TA98
- Positive control substance:
- other: 4-Nitroquinoline-1-oxide
- Remarks:
- absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 1 μg/plate for TA100, 2 μg/plate for TA1535 and TA1537, 10 μg/plate for WP2uvrA
- Positive control substance:
- other: 2-Aminoanthracene
- Remarks:
- presence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 5 μg/plate for TA98
- Positive control substance:
- benzo(a)pyrene
- Remarks:
- presence of S9-mix
- Details on test system and experimental conditions:
- Test for Mutagenicity: Experiment 1 – Plate Incorporation Method
Without Metabolic Activation
A 0.1 mL aliquot of the appropriate concentration of test item, solvent vehicle or 0.1 mL of the appropriate positive control was added together with 0.1 mL of the bacterial strain culture, 0.5 mL of phosphate buffer and 2 mL of molten, trace amino-acid supplemented media. These were then mixed and overlayed onto a Vogel-Bonner agar plate. Negative (untreated) controls were also performed on the same day as the mutation test. Each concentration of the test item, appropriate positive, vehicle and negative controls, and each bacterial strain, was assayed using triplicate plates.
With Metabolic Activation
The procedure was the same as described previously except that following the addition of the test item formulation and bacterial culture, 0.5 mL of S9-mix was added to the molten, trace amino-acid supplemented media instead of phosphate buffer.
Incubation and Scoring
All of the plates were incubated at 37 ± 3 °C for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity).
Test for Mutagenicity: Experiment 2 – Pre-Incubation Method
Without Metabolic Activation
A 0.1 mL aliquot of the appropriate bacterial strain culture, 0.5 mL of phosphate buffer and 0.1 mL of the appropriate concentration of test item formulation, solvent vehicle or 0.1 mL of appropriate positive control were incubated at 37 ± 3 °C for 20 minutes (with shaking) prior to addition of 2 mL of molten, trace amino-acid supplemented media and subsequent plating onto Vogel-Bonner plates. Negative (untreated) controls were also performed on the same day as the mutation test employing the plate incorporation method. All testing for this experiment was performed in triplicate.
With Metabolic Activation
The procedure was the same as described previously except that following the addition of the test item formulation and bacterial strain culture, 0.5 mL of S9-mix was added to the tube instead of phosphate buffer, prior to incubation at 37 ± 3 °C for 20 minutes (with shaking) and addition of molten, trace amino-acid supplemented media. All testing for this experiment was performed in triplicate.
Incubation and Scoring
All of the plates were incubated at 37 ± 3 °C for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity).
The negative (untreated) controls were performed to assess the spontaneous revertant colony rate. The solvent and negative controls were performed in triplicate.
The positive control items used demonstrated a direct and indirect acting mutagenic effect depending on the presence or absence of metabolic activation. The positive controls were performed in triplicate. - Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1. A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).
2. A reproducible increase at one or more concentrations.
3. Biological relevance against in-house historical control ranges.
4. A fold increase greater than two times the concurrent solvent control for all strains (especially if accompanied by an out-of-historical range response (Cariello and Piegorsch, 1996)).
5. Statistical analysis of data as determined by UKEMS (Mahon et al., 1989).
A test item will be considered non-mutagenic (negative) in the test system if the above criteria are not met.
Although most experiments will give clear positive or negative results, in some instances the data generated will prohibit making a definite judgment about test item activity. Results of this type will be reported as equivocal. - Statistics:
- Statistical significance was confirmed by using Dunnetts Regression Analysis (* = p < 0.05) for those values that indicate statistically significant increases in the frequency of revertant colonies compared to the concurrent solvent control.
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Prior to use, the master strains were checked for characteristics, viability and spontaneous reversion rate (all were found to be satisfactory). The amino acid supplemented top agar and the S9-mix used in both experiments was shown to be sterile. The test item formulation was also shown to be sterile. These data are not given in the report.
The vehicle (sterile distilled water) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with and without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
Experiment 1 (plate incorporation)
The maximum dose level of the test item in the first experiment was selected as the OECD TG 471 recommended dose level of 5000 μg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix).
No test item precipitate was observed on the plates at any of the doses tested in either the presence or absence of metabolic activation (S9-mix).
There were no significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix).
Experiment 2 (pre-incubation)
The maximum dose level of the test item in the second experiment was the same as for Experiment 1 (5000 μg/plate).
There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix).
No test item precipitate was observed on the plates at any of the doses tested in either the presence or absence of metabolic activation (S9-mix).
There were no significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix). - Conclusions:
- In this Reverse Mutation Assay ‘Ames Test’ using strains of Salmonella typhimurium and Escherichia coli (OECD TG 471) the test item Diethoxymethane did not induce an increase in the frequency of revertant colonies at any of the dose levels used either with or without metabolic activation (S9-mix). Under the conditions of this test Diethoxymethane was concluded as non-mutagenic.
- Executive summary:
Introduction
The test method was designed to be compatible with the guidelines for bacterial mutagenicity testing published by the major Japanese Regulatory Authorities including METI, MHLW and MAFF, the OECD Guidelines for Testing of Chemicals No. 471 "Bacterial Reverse Mutation Test", Method B13/14 of Commission Regulation (EC) number 440/2008 of 30 May 2008 and the USA, EPA OCSPP harmonized guideline - Bacterial Reverse Mutation Test.
Methods
Salmonella typhimurium strains TA1535, TA1537, TA98 and TA100 and Escherichia coli strain WP2uvrA were treated with the test item using both the Ames plate incorporation and pre-incubation methods at up to eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). The dose range for Experiment 1 (plate incorporation) was based on OECD TG 471 and was 1.5 to 5000 μg/plate. The experiment was repeated on a separate day (pre-incubation method) using fresh cultures of the bacterial strains and fresh test item formulations. The dose range was amended following the results of Experiment 1 and was 15 to 5000 μg/plate. Six test item concentrations per bacterial strain were selected in Experiment 2 in order to achieve both four non-toxic dose levels and the potential toxicity of the test item following the change in test methodology.
Results
The vehicle (sterile distilled water) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with and without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The maximum dose level of the test item in the first experiment was selected as the OECD TG 471 recommended dose level of 5000 μg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test (plate incorporation method).
Based on the results of Experiment 1, the same maximum dose level (5000 μg/plate) was employed in the second mutation test (pre-incubation method). Similarly, there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix).
No test item precipitate was observed on the plates at any of the doses tested in either the presence or absence of metabolic activation (S9-mix) in Experiments 1 and 2.
There were no significant increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1 (plate incorporation method).
Similarly, no significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 2 (pre-incubation method).
Conclusion
Diethoxymethane was considered to be non-mutagenic under the conditions of this test.
- Endpoint:
- in vitro cytogenicity / micronucleus study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Experimental start date 28 July 2017 Experimental completion date 17 November 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 487 (In vitro Mammalian Cell Micronucleus Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian cell micronucleus test
- Specific details on test material used for the study:
- Identification: Ethylal
Chemical name: Diethoxymethane
CAS Number: 462-95-3
Physical state/Appearance: Clear colorless liquid
Storage Conditions: Approximately 4 °C in the dark under nitrogen
Intended use/Application: Not supplied
No correction for purity was made. - Target gene:
- not applicable
- Species / strain / cell type:
- primary culture, other: whole blood
- Details on mammalian cell type (if applicable):
- Cells
For each experiment, sufficient whole blood was drawn from the peripheral circulation of a non-smoking volunteer (18-35) who had been previously screened for suitability. The volunteer had not knowingly been exposed to high levels of radiation or hazardous chemicals and had not knowingly recently suffered from a viral infection. Based on over 20 years in-house data for cell cycle times for lymphocytes using BrdU (bromodeoxyuridine) incorporation to assess the number of first, second and third division metaphase cells to calculate the average generation time (AGT) for human lymphocytes it is considered to be approximately 16 hours. Therefore using this average the in-house exposure time for the experiments for 1.5 x AGT is 24 hours.
The details of the donors used are:
Preliminary Toxicity Test: male, aged 29 years
Main Experiment: female, aged 25 years
Cell Culture
Cells (whole blood cultures) were grown in Eagle's minimal essential medium with HEPES buffer (MEM), supplemented “in-house” with L-glutamine, penicillin/streptomycin, amphotericin B and 10% fetal bovine serum (FBS), at approximately 37 ºC with 5% CO2 in humidified air. The lymphocytes of fresh heparinized whole blood were stimulated to divide by the addition of phytohaemagglutinin (PHA). - Cytokinesis block (if used):
- Cytochalasin B
- Metabolic activation:
- with and without
- Metabolic activation system:
- standard metabolizing system (S9)
- Test concentrations with justification for top dose:
- Preliminary Toxicity Test
The dose range of test item used was 0, 4.07, 8.14, 16.28, 32.56, 65.13, 130.25, 260.5, 521 and 1042 μg/mL.
Main Experiment
The dose range of test item used for all three exposures was 0, 65.13, 130.25, 260.5, 521, 781.5, 1042 μg/mL. - Vehicle / solvent:
- The test item was miscible in aqueous media (MEM) at 10.42 mg/mL by mixing on a vortex for approximately 10 seconds in a solubility check performed in-house. The highest concentration of the test item tested in this study was 10.42 mg/mL.
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Minimal Essential Medium
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.2 μg/mL for 4-hour exposure
- Positive control substance:
- mitomycin C
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Minimal Essential Medium
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.075 μg/mL for 24-hour continuous exposure
- Positive control substance:
- other: Demecolcine
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Minimal Essential Medium
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 5 μg/mL for 4-hour exposure
- Positive control substance:
- cyclophosphamide
- Remarks:
- Presence of S9-mix
- Details on test system and experimental conditions:
- Culture conditions
Duplicate lymphocyte cultures (A and B) were established for each dose level by mixing the following components, giving, when dispensed into sterile plastic flasks for each culture:
8.05-9.05 mL MEM, 10% (FBS)
0.1 mL Li-heparin
0.1 mL phytohaemagglutinin
0.75 mL heparinized whole blood
4-Hour Exposure With Metabolic Activation (S9)
After approximately 48 hours incubation at approximately 37 ºC, 5% CO2 in humidified air, the cultures were transferred to tubes and centrifuged. Approximately 9 mL of the culture medium was removed, reserved, and replaced with the required volume of MEM (including serum) and 1.0 mL of the appropriate solution of vehicle control or test item was added to each culture. For the positive control, 0.1 mL of the appropriate solution was added to the cultures. 1.0 mL of 20% S9-mix (i.e. 2% final concentration of S9 in standard co-factors) was added to the cultures of the Preliminary Toxicity Test and the Main Experiment. All cultures were then returned to the incubator. The nominal total volume of each culture was 10 mL.
After 4 hours at approximately 37 ºC, the cultures were centrifuged, the treatment medium removed by suction and replaced with an 8 mL wash of MEM culture medium. After a further centrifugation the wash medium was removed by suction and replaced with the reserved original culture medium, supplemented with Cytochalasin B at a final concentration of 4.5 μg/mL, and then incubated for a further 24 hours.
4-Hour Exposure Without Metabolic Activation (S9)
After approximately 48 hours incubation at approximately 37 ºC with 5% CO2 in humidified air, the cultures were decanted into tubes and centrifuged. Approximately 9 mL of the culture medium was removed and reserved. The cells were then resuspended in the required volume of fresh MEM (including serum) and dosed with 1.0 mL of the appropriate vehicle control, test item solution or 0.1 mL of positive control solution. The nominal total volume for each culture was 10 mL.
After 4 hours at approximately 37 ºC, the cultures were centrifuged, the treatment medium was removed by suction and replaced with an 8 mL wash of MEM culture medium. After a further centrifugation the wash medium was removed by suction and replaced with the reserved original culture medium, supplemented with Cytochalasin B, at a final concentration of 4.5 μg/mL, and then incubated for a further 24 hours.
24-Hour Exposure Without Metabolic Activation (S9)
The exposure was continuous for 24 hours in the absence of metabolic activation. Therefore, when the cultures were established the culture volume was a nominal 9 mL. After approximately 48 hours incubation the cultures were removed from the incubator and dosed with 1.0 mL of vehicle control, test item dose solution or 0.1 mL of positive control solution. The nominal total volume of each culture was 10 mL. The cultures were then incubated for 24 hours, the tubes and the cells washed in MEM before resuspension in fresh MEM with serum. At this point Cytochalasin B was added at a final concentration of 4.5 μg/mL, and then the cells were incubated for a further 24 hours.
The extended exposure detailed above does not follow the suggested cell treatment schedule in the Guideline. This is because it avoids any potential interaction between Cytochalasin B and the test item during exposure to the cells and any effect this may have on the activity or response. Additionally, as the stability or reactivity of the test item is unknown prior to the start of the study this modification of the schedule is considered more effective and reproducible due to the in-house observations on human lymphocytes and their particular growth characteristics in this study type and also the significant laboratory historical control data using the above format.
The preliminary toxicity test was performed using the exposure conditions as described for the Main Experiment but using single cultures only, whereas the Main Experiment used replicate cultures.
Preliminary Toxicity Test
Three exposure groups were used:
i) 4-hour exposure to the test item without S9-mix, followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
ii) 4-hour exposure to the test item with S9-mix (2%), followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
iii) 24-hour continuous exposure to the test item without S9-mix, followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
The dose range of test item used was 0, 4.07, 8.14, 16.28, 32.56, 65.13, 130.25, 260.5, 521 and 1042 μg/mL.
Parallel flasks, containing culture medium without whole blood, were established for the three exposure conditions so that test item precipitate observations could be made. Precipitate observations were recorded at the beginning and end of the exposure periods.
Using a qualitative microscopic evaluation of the microscope slide preparations from each treatment culture, appropriate dose levels were selected for the evaluation of the frequency of binucleate cells and to calculate the cytokinesis block proliferation index (CBPI). Coded slides were evaluated for the CBPI. The CBPI data were used to estimate test item toxicity and for selection of the dose levels for the experiments of the main test.
Main Experiment
Three exposure groups were used for Main Experiment:
i) 4-hour exposure to the test item without S9-mix, followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
ii) 4-hour exposure to the test item with S9-mix (2%), followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
iii) 24-hour continuous exposure to the test item without S9-mix, followed by a 24-hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
The dose range of test item used for all three exposures was 0, 65.13, 130.25, 260.5, 521, 781.5, 1042 μg/mL.
Cell Harvest
At the end of the Cytochalasin B treatment period the cells were centrifuged, the culture medium was drawn off and discarded, and the cells resuspended in MEM. The cells were then treated with a mild hypotonic solution (0.0375M KCl) before being fixed with fresh methanol/glacial acetic acid (19:1 v/v). The fixative was changed at least three times and the cells stored at approximately 4 ºC prior to slide making.
Preparation of Microscope Slides
The lymphocytes were re-suspended in several mL of fresh fixative before centrifugation and re-suspension in a small amount of fixative. Several drops of this suspension were dropped onto clean, wet microscope slides and left to air dry. Each slide was permanently labelled with the appropriate identification data.
Staining
When the slides were dry they were stained in 5% Giemsa for 5 minutes, rinsed, dried and a cover slip applied using mounting medium. - Evaluation criteria:
- Providing that all of the acceptability criteria are fulfilled, a test item is considered to be clearly negative if, in most/all of the experimental conditions examined:
1. None of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control.
2. There is no dose-related increase.
3. The results in all evaluated dose groups should be within the range of the laboratory historical control data.
Providing that all of the acceptability criteria are fulfilled, a test item may be considered to be clearly positive, if in any of the experimental conditions examined, there is one or more of the following applicable:
1. At least one of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control.
2. There is an increase which can be considered to be dose-related.
3. The results are substantially outside the range of the laboratory historical negative control data.
When all the criteria are met, the test item is considered able to induce chromosome breaks and/or gain or loss in this test system.
There is no requirement for verification of a clear positive or negative response.
In case the response is neither clearly negative nor clearly positive as described above or in order to assist in establishing the biological relevance of a result, the data should be evaluated by expert judgement and/or further investigations.
Test items that induce micronuclei in the MNvit test may do so because they induce chromosome breakage, chromosome loss, or a combination of the two. Further analysis using anti-kinetechore antibodies, centromere specific in situ probes, or other methods can be used to determine whether the mechanism of micronucleus induction is due to clastogenic and/or aneugenic activity. - Statistics:
- The frequency of binucleate cells with micronuclei was compared, where necessary, with the concurrent vehicle control value using the Chi-squared Test on observed numbers of cells with micronuclei. Other statistical analyses may be used if appropriate (Hoffman et al., 2003). A toxicologically significant response was recorded when the p value calculated from the statistical analysis of the frequency of binucleate cells with micronuclei was less than 0.05 and there was a dose-related increase in the frequency of binucleate cells with micronuclei which was reproducible.
- Species / strain:
- primary culture, other: whole blood
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- Preliminary Toxicity Test (Table 1)
The dose range for the Preliminary Toxicity Test was 4.07 to 1042 μg/mL. The molecular weight of the test item was given as 104.15, therefore, the maximum dose level was 1042 μg/mL, which was calculated to be equivalent to the 10mM concentration (the maximum recommended dose level).
No precipitate of the test item was observed in the parallel blood-free cultures at the end of the exposure at any dose level tested in any of the exposure groups.
Microscopic assessment of the slides prepared from the exposed cultures showed that binucleate cells were present at up to the maximum concentration in all three exposure groups. The test item induced no evidence of toxicity in any of the exposure groups.
The selection of the maximum dose level for the Main Experiment was, therefore, based on the maximum recommended dose level (1042 μg/mL) for all three exposure group.
Micronucleus Test – Main Experiment
As during the Preliminary Toxicity Test, there were binucleate cells suitable for scoring at the maximum dose level of test item, 1042 μg/mL, for all three exposure groups.
No precipitate of the test item was observed in the parallel blood-free cultures at the end of the exposure at any dose level tested in any of the exposure groups.
The CBPI data confirm the qualitative observations in that no dose-related inhibition of CBPI was observed Tables 2 to 6).
The maximum dose level selected for analysis of binucleate cells was the maximum recommended dose level (1042 μg/mL) for all three exposure groups.
The vehicle control cultures had frequencies of cells with micronuclei within the expected range. The positive control items induced statistically significant increases in the frequency of cells with micronuclei. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item did not induce any statistically significant increases in the frequency of binucleate cells with micronuclei, either in the absence or presence of metabolic activation. - Conclusions:
- Under the conditions of this test, the test item, Ethylal, did not induce a statistically significant increase in the frequency of binucleate cells with micronuclei in either the absence or presence of a metabolizing system. The test item was therefore considered to be non-clastogenic and non-aneugenic to human lymphocytes in vitro.
- Executive summary:
Introduction
This report describes the results of an in vitro study for the detection of the clastogenic and aneugenic potential of the test item on the nuclei of normal human lymphocytes.
Methods
Duplicate cultures of human lymphocytes, treated with the test item, were evaluated for micronuclei in binucleate cells at three dose levels, together with vehicle and positive controls. Three exposure conditions in a single experiment were used for the study using a 4-hour exposure in the presence and absence of a standard metabolizing system (S9) at a 2%
final concentration and a 24-hour exposure in the absence of metabolic activation. At the end of the exposure period, the cell cultures were washed and then incubated for a further 24 hours in the presence of Cytochalasin B.
The dose levels used in the Main Experiment were selected using data from the preliminary toxicity test where the results indicated that the maximum concentration should be the maximum recommended limit (1042 µg/mL). The dose levels selected for the Main Test were as follows:
Group
Final concentration of test item Ethylal (µg/mL)
4-hour without S9
0, 65.13, 130.25, 260.5, 521, 781.5, 1042
4-hour with S9 (2%)
24-hour without S9
Results
All vehicle (Eagle's minimal essential medium with HEPES buffer (MEM)) controls had frequencies of cells with micronuclei within the range expected for normal human lymphocytes.
The positive control items induced statistically significant increases in the frequency of cells with micronuclei. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item was non-toxic to human lymphocytes and did not induce any statistically significant increases in the frequency of cells with micronuclei, using a dose range that included a dose level that was the maximum recommended dose level.
Conclusion
Under the conditions of this study, the test item, Ethylal, was considered to be non-clastogenic and non-aneugenic to human lymphocytes in vitro.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 02 August 2018 - 29 August 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 490 (In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian cell gene mutation tests using the thymidine kinase gene
- Specific details on test material used for the study:
- Clear colourless liquid
- Target gene:
- Thymidine kinase, TK +/-
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- The L5178Y TK+/- 3.7.2c mouse lymphoma cell line was obtained from Dr. J. Cole of the MRC Cell Mutation Unit at the University of Sussex, Brighton, UK. The cells were originally obtained from Dr. D. Clive of Burroughs Wellcome (USA) in October 1978 and were frozen in liquid nitrogen at that time.
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- Lot No. PB/βNF S9 29/03/18 was used in this study, and was pre-prepared in-house (outside the confines of the study) following standard procedures. Prior to use, each batch of S9 was tested for its capability to activate known mutagens in the Ames test.
S9-mix was prepared by mixing S9, NADP (5 mM), G-6-P (5 mM), KCl (33 mM) and MgCl2 (8 mM) in R0.
20% S9-mix (i.e. 2% final concentration of S9) was added to the cultures of the Preliminary Toxicity Test and Mutagenicity Test. - Test concentrations with justification for top dose:
- The dose range of test item used in the main test was selected following the results of a preliminary toxicity test at a concentration range of 4.07 to 1042 μg/mL. The maximum dose level used in the Mutagenicity Test was the 10 mM Maximum Recommended Dose level (MRD).
The dose levels plated for viability and expression of mutant colonies were as follows: 32.56, 65.13, 130.25, 260.5, 521, 1042 μg/mL - Vehicle / solvent:
- R0 culture media
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- ethylmethanesulphonate
- Details on test system and experimental conditions:
- The cells were counted and processed to give 1 x 10e6 cells/mL in 10 mL aliquots in R10 medium in sterile plastic universals for the 4-hour exposure groups in both the absence and presence of metabolic activation, and 0.3 x 10e6 cells/mL in 10 mL cultures were established in 25 cm2 tissue culture flasks for the 24-hour exposure group in the absence of metabolic activation. The exposures were performed in duplicate (A + B), both with and without metabolic activation (2% S9 final concentration) at six dose levels of the test item 32.56 to 1042 μg/mL for all three exposure groups, vehicle and positive controls. To each universal was added 2 mL of S9 mix if required, 2.0 mL of the exposure dilutions, (0.2 mL or 0.15 mL for the positive controls), and sufficient R0 medium to bring the total volume to 20 mL (R10 was used for the 24 hour exposure group).
The exposure vessels were incubated at 37 °C for 4 or 24 hours with continuous shaking using an orbital shaker within an incubated hood.
Microtitre plates were scored using a magnifying mirror box after ten to twelve days incubation at 37 °C with 5% CO2 in air. The number of positive wells (wells with colonies) was recorded together with the total number of scorable wells (normally 96 per plate). The numbers of small and large colonies seen in the TFT mutation plates were also recorded as the additional information may contribute to an understanding of the mechanism of action of the test item. Colonies were scored manually by eye using qualitative judgment. Large colonies were defined as those that covered approximately ¼ to ¾ of the surface of the well and were generally no more than one or two cells thick. In general, all colonies less than 25% of the average area of the large colonies were scored as small colonies. Small colonies are normally observed to be more than two cells thick. To assist the scoring of the TFT mutant colonies 0.025 mL of thiazolyl blue tetrazolium bromide (MTT) solution, 2.5 mg/mL in phosphate buffered saline (PBS), was added to each well of the mutation plates. The plates were incubated for two hours. MTT is a vital stain that is taken up by viable cells and metabolised to give a brown/black color, thus aiding the visualization of the mutant colonies, particularly the small colonies. - Rationale for test conditions:
- The use of cultured mammalian cells for mutation studies may give a measure of the intrinsic response of the mammalian genome and its maintenance processes to mutagens. Such techniques have been used for many years with widely different cell types and loci. The thymidine kinase heterozygote system, TK +/- to TK -/-, was described by Clive et al., (1972) and is based upon the L5178Y mouse lymphoma cell line established by Fischer (1958). This system has been extensively validated (Clive et al., 1979; Amacher et al., 1980; Jotz and Mitchell, 1981).
Ref:
Amacher, D.E., Paillet, S.C., Turner, G.N., Ray, V.A. and Salsburg, D.S. (1980) Point mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells. 2. Test validation and interpretation, Mutation Res., 72, pp 447-474.
Clive, D., Flamm, W.G., Machesko, M.R. and Bernheim, N.J. (1972) A mutational assay system using the thymidine kinase locus in mouse lymphoma cells. Mutation Res., 16, pp 77-87.
Clive, D., Johnson, K.O., Spector, J.F.S., Batson, A.G. and Brown, M.M.M. (1979) Validation and characterisation of the L5178Y TK +/- mouse lymphoma mutagen assay system. Mutation Res. 59, pp. 61-108.
Fischer, G.A. (1958) Ann. NY Acad. Sci., 76, 673-680.
JOTZ, M.M. and MITCHELL, A.D. (1981) Effects of 20 Coded Chemicals on the forward mutation frequency at the thymidine kinase locus in L5178Y mouse lymphoma cells. In: Evaluation of Short-term Tests for Carcinogens [de Serres F J and Ashby J (Eds)], Elsevier/North Holland, New York, pp 580-593. - Evaluation criteria:
- 1. The majority of the plates, for both viability (%V) and TFT resistance, are analyzable.
2. The absolute viability (%V) at the time of mutant selection of the solvent controls is 65-120 %.
3. The total suspension growth of the solvent control following 4 hour exposure should be in the range of 8 - 32. Following 24 hour exposure the total suspension growth should be in the range of 32 - 180.
4. The in-house vehicle control mutant frequency is in the range of 50 – 170 x 10-6 cells. Vehicle control results should ideally be within this range, although minor errors in cell counting and dilution, or exposure to the metabolic activation system, may cause this to be slightly elevated. Experiments where the vehicle control values are markedly greater than 200 x 10-6 mutant frequency per survivor are not acceptable and will be repeated.
5. Every test should also be evaluated as to whether the positive controls (EMS and CP) meet at least one of the following two acceptance criteria developed by the IWGT workgroup:
The positive control should demonstrate an absolute increase in total MF, that is, an increase above the spontaneous background MF [an induced MF (IMF)] of at least 300 x 10-6. At least 40% of the IMF should be reflected in the small colony MF.
The positive control has an increase in the small colony MF of at least 150 x 10-6 above that seen in the concurrent untreated/solvent control (a small colony IMF of 150 x 10-6).
6. The upper limit of cytotoxicity observed in the positive control culture should be the same as for the experimental cultures
7. The upper test item concentrations will be 10mM, 2 mg/mL or 2μL/mL whichever is the lowest. Precipitating dose levels will not be tested beyond the onset of precipitation regardless of the presence of toxicity beyond this point. In the absence of precipitate and if toxicity occurs, the highest concentration should lower the Relative Total Growth (RTG) to approximately 10 to 20 % of survival. - Statistics:
- The experimental data was analyzed using a dedicated computer program, Mutant 240C by York Electronic Research, which follows the statistical guidelines recommended by the UKEMS (Robinson W D et al., 1989). The statistical package used indicates the presence of statistically significant increases and linear-trend events.
- Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Preliminary test:
The dose range of the test item used in the preliminary toxicity test was 1.25 to 320 μg/mL.
There was no evidence dose-related reductions in the Relative Suspension Growth (%RSG) of cells treated with the test item in the 4-hour exposure groups either in the absence or presence of metabolic activation when groups compared to the concurrent vehicle control groups. There was a modest reduction in %RSG in the 24-hour exposure group. No precipitate was observed. Therefore, the dose levels selected for the main test was up to the maximum recommended dose level of 1042 μg/mL for all three exposure groups.
Main test:
There was no evidence of marked dose related toxicity following exposure to the test item in the 4-hour exposure groups in either the absence or presence of metabolic activation as indicated by the %RSG and RTG values. As was observed in the preliminary toxicity test there was a modest reduction in %RSG and RTG values in the 24-hour exposure group. Acceptable levels of toxicity were seen with the positive control substances. No precipitate was observed.
The vehicle controls had mutant frequency values that were considered acceptable for the L5178Y cell line at the TK +/- locus. The positive controls produced marked increases in the mutant frequency per viable cell achieving the acceptability criterion, indicating that the test system was operating satisfactorily, and that the metabolic activation system was functional. (tables 1 - 10) - Conclusions:
- The test item, Ethylal did not induce any increases in the mutant frequency at the TK +/- locus in L5178Y cells that exceeded the Global Evaluation Factor (GEF) of 126 x 10-6, consequently it is considered to be non-mutagenic in this assay.
Referenceopen allclose all
Spontaneous Mutation Rates (ConcurrentNegativeControls)
Experiment1
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
119 |
|
16 |
|
26 |
|
27 |
|
9 |
|
118 |
(127) |
12 |
(15) |
23 |
(30) |
21 |
(25) |
11 |
(10) |
144 |
|
16 |
|
41 |
|
28 |
|
10 |
|
|
28 |
|
|
||||||
20 |
(25)† |
||||||||
26 |
|
Experiment 2
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||
107 |
|
18 |
|
24 |
|
27 |
|
12 |
|
141 |
(131) |
23 |
(18) |
25 |
(31) |
20 |
(25) |
17 |
(13) |
146 |
|
14 |
|
43 |
|
28 |
|
9 |
|
† Experimental procedure repeated at a later date (with metabolic activation (S9 -mix)) due to contamination in the original test
Test Results: Experiment 1 – Without MetabolicActivation(Plate Incorporation)
Test Period |
From: 13 March 2018 |
To: 16 March 2018 |
|||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
|||||||||
Base-pair substitution strains |
Frameshift strains |
||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||||
Solvent Control (Water) |
150 150 120 |
(140) 17.3# |
14 17 14 |
(15) 1.7 |
42 30 33 |
(35) 6.2 |
24 26 25 |
(25) 1.0 |
12 12 7 |
(10) 2.9 |
|
1.5 µg |
150 151 118 |
(140) 18.8 |
14 17 18 |
(16) 2.1 |
37 36 31 |
(35) 3.2 |
25 17 20 |
(21) 4.0 |
6 9 12 |
(9) 3.0 |
|
5 µg |
114 133 140 |
(129) 13.5 |
17 20 18 |
(18) 1.5 |
24 19 36 |
(26) 8.7 |
20 34 16 |
(23) 9.5 |
14 6 8 |
(9) 4.2 |
|
15 µg |
127 145 150 |
(141) 12.1 |
15 21 22 |
(19) 3.8 |
37 33 42 |
(37) 4.5 |
19 32 27 |
(26) 6.6 |
5 12 11 |
(9) 3.8 |
|
50 µg |
129 132 135 |
(132) 3.0 |
16 11 14 |
(14) 2.5 |
33 29 30 |
(31) 2.1 |
33 21 28 |
(27) 6.0 |
8 4 8 |
(7) 2.3 |
|
150 µg |
138 144 137 |
(140) 3.8 |
18 21 12 |
(17) 4.6 |
37 30 36 |
(34) 3.8 |
23 23 31 |
(26) 4.6 |
10 9 13 |
(11) 2.1 |
|
500 µg |
138 128 144 |
(137) 8.1 |
14 14 17 |
(15) 1.7 |
28 23 28 |
(26) 2.9 |
30 29 30 |
(30) 0.6 |
16 10 5 |
(10) 5.5 |
|
1500 µg |
129 148 155 |
(144) 13.5 |
13 10 14 |
(12) 2.1 |
34 34 36 |
(35) 1.2 |
15 12 23 |
(17) 5.7 |
9 6 12 |
(9) 3.0 |
|
5000 µg |
122 130 133 |
(128) 5.7 |
7 12 21 |
(13) 7.1 |
37 35 29 |
(34) 4.2 |
29 19 14 |
(21) 7.6 |
8 17 4 |
(10) 6.7 |
|
Positive controls S9-Mix (-) |
Name DoseLevel No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
|||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
|||||||
753 740 719 |
(737) 17.2 |
499 140 552 |
(397) 224.1 |
715 675 657 |
(682) 29.7 |
315 315 473 |
(368) 91.2 |
220 106 212 |
(179) 63.6 |
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
# Standarddeviation
Test Results: Experiment 1 – With MetabolicActivation(Plate Incorporation)
Test Period |
From: 13 March 2018 From: 19 March 2018† |
To: 16 March 2018 To: 22 March 2018† |
|||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
|||||||||
Base-pair substitution strains |
Frameshift strains |
||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98† |
TA1537 |
|||||||
Solvent Control (Water) |
124 142 147 |
(138) 12.1# |
14 15 16 |
(15) 1.0 |
36 36 29 |
(34) 4.0 |
24 22 35 |
(27) 7.0 |
9 9 8 |
(9) 0.6 |
|
1.5 µg |
127 133 118 |
(126) 7.5 |
14 21 17 |
(17) 3.5 |
35 40 33 |
(36) 3.6 |
25 22 27 |
(25) 2.5 |
9 10 9 |
(9) 0.6 |
|
5 µg |
145 129 143 |
(139) 8.7 |
16 18 8 |
(14) 5.3 |
28 44 37 |
(36) 8.0 |
41 33 37 |
(37) 4.0 |
12 13 10 |
(12) 1.5 |
|
15 µg |
102 130 133 |
(122) 17.1 |
20 12 24 |
(19) 6.1 |
36 45 36 |
(39) 5.2 |
38 30 34 |
(34) 4.0 |
11 10 12 |
(11) 1.0 |
|
50 µg |
146 129 120 |
(132) 13.2 |
16 24 12 |
(17) 6.1 |
36 34 40 |
(37) 3.1 |
32 37 38 |
(36) 3.2 |
6 5 10 |
(7) 2.6 |
|
150 µg |
144 143 145 |
(144) 1.0 |
10 12 13 |
(12) 1.5 |
33 37 28 |
(33) 4.5 |
33 22 43 |
(33) 10.5 |
6 6 7 |
(6) 0.6 |
|
500 µg |
136 137 145 |
(139) 4.9 |
10 8 14 |
(11) 3.1 |
33 42 38 |
(38) 4.5 |
26 28 31 |
(28) 2.5 |
6 10 11 |
(9) 2.6 |
|
1500 µg |
133 144 129 |
(135) 7.8 |
12 11 20 |
(14) 4.9 |
39 44 39 |
(41) 2.9 |
34 30 28 |
(31) 3.1 |
8 11 15 |
(11) 3.5 |
|
5000 µg |
123 109 136 |
(123) 13.5 |
9 17 22 |
(16) 6.6 |
28 47 44 |
(40) 10.2 |
20 28 38 |
(29) 9.0 |
8 4 9 |
(7) 2.6 |
|
Positive controls S9-Mix (+) |
Name DoseLevel No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
|||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
|||||||
2755 2870 2770 |
(2798) 62.5 |
341 381 336 |
(353) 24.7 |
328 326 319 |
(324) 4.7 |
195 184 171 |
(183) 12.0 |
493 440 464 |
(466) 26.5 |
† Experimental procedure repeated at a later date due to contamination in the original test
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
# Standarddeviation
Test Results: Experiment 2 – Without MetabolicActivation(Pre- Incubation)
Test Period |
From: 26 March 2018 |
To: 29 March 2018 |
|||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
|||||||||
Base-pair substitution strains |
Frameshift strains |
||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||||
Solvent Control (Water) |
152 129 144 |
(142) 11.7# |
9 13 13 |
(12) 2.3 |
38 27 35 |
(33) 5.7 |
24 27 15 |
(22) 6.2 |
12 9 16 |
(12) 3.5 |
|
15 µg |
130 157 132 |
(140) 15.0 |
10 6 15 |
(10) 4.5 |
31 28 17 |
(25) 7.4 |
18 30 18 |
(22) 6.9 |
11 11 10 |
(11) 0.6 |
|
50 µg |
142 150 132 |
(141) 9.0 |
16 11 11 |
(13) 2.9 |
29 30 24 |
(28) 3.2 |
18 27 19 |
(21) 4.9 |
7 6 8 |
(7) 1.0 |
|
150 µg |
137 129 153 |
(140) 12.2 |
11 9 7 |
(9) 2.0 |
28 29 35 |
(31) 3.8 |
22 19 28 |
(23) 4.6 |
16 10 10 |
(12) 3.5 |
|
500 µg |
122 133 130 |
(128) 5.7 |
12 14 16 |
(14) 2.0 |
33 36 26 |
(32) 5.1 |
16 16 15 |
(16) 0.6 |
8 8 5 |
(7) 1.7 |
|
1500 µg |
115 150 154 |
(140) 21.5 |
13 13 12 |
(13) 0.6 |
33 21 36 |
(30) 7.9 |
24 26 17 |
(22) 4.7 |
15 12 14 |
(14) 1.5 |
|
5000 µg |
144 150 130 |
(141) 10.3 |
13 13 13 |
(13) 0.0 |
38 41 38 |
(39) 1.7 |
17 20 20 |
(19) 1.7 |
13 11 13 |
(12) 1.2 |
|
Positive controls S9-Mix (-) |
Name DoseLevel No. of Revertants |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
|||||
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
|||||||
800 780 710 |
(763) 47.3 |
500 507 544 |
(517) 23.6 |
790 789 723 |
(767) 38.4 |
340 368 422 |
(377) 41.7 |
571 921 739 |
(744) 175.0 |
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
# Standarddeviation
Test Results: Experiment 2 – With MetabolicActivation(Pre- Incubation)
Test Period |
From: 26 March 2018 |
To: 29 March 2018 |
|||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
|||||||||
Base-pair substitution strains |
Frameshift strains |
||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||||
Solvent Control (Water) |
133 143 127 |
(134) 8.1# |
14 17 19 |
(17) 2.5 |
40 28 41 |
(36) 7.2 |
32 29 29 |
(30) 1.7 |
14 8 13 |
(12) 3.2 |
|
15 µg |
149 147 145 |
(147) 2.0 |
8 10 11 |
(10) 1.5 |
38 39 50 |
(42) 6.7 |
21 23 25 |
(23) 2.0 |
11 13 13 |
(12) 1.2 |
|
50 µg |
128 130 142 |
(133) 7.6 |
12 12 12 |
(12) 0.0 |
30 40 45 |
(38) 7.6 |
29 24 28 |
(27) 2.6 |
15 12 13 |
(13) 1.5 |
|
150 µg |
132 143 152 |
(142) 10.0 |
16 10 13 |
(13) 3.0 |
32 38 37 |
(36) 3.2 |
29 35 24 |
(29) 5.5 |
12 14 11 |
(12) 1.5 |
|
500 µg |
135 139 151 |
(142) 8.3 |
9 20 11 |
(13) 5.9 |
47 33 45 |
(42) 7.6 |
43 34 28 |
(35) 7.5 |
13 10 13 |
(12) 1.7 |
|
1500 µg |
145 115 150 |
(137) 18.9 |
8 10 15 |
(11) 3.6 |
45 34 34 |
(38) 6.4 |
24 23 24 |
(24) 0.6 |
12 7 10 |
(10) 2.5 |
|
5000 µg |
150 136 129 |
(138) 10.7 |
12 13 13 |
(13) 0.6 |
41 37 47 |
(42) 5.0 |
26 34 29 |
(30) 4.0 |
7 14 9 |
(10) 3.6 |
|
Positive controls S9-Mix (+) |
Name DoseLevel No. of Revertants |
2AA |
2AA |
2AA |
BP |
2AA |
|||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
|||||||
2152 2108 1971 |
(2077) 94.4 |
343 333 332 |
(336) 6.1 |
261 206 281 |
(249) 38.8 |
158 160 138 |
(152) 12.2 |
400 408 413 |
(407) 6.6 |
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
# Standarddeviation
The dose levels of the controls and the test item are given in the table below:
Group | Final concentration of test item Ethylal (µg/mL) |
4-hour without S9 | 0*,65.13, 130.25, 260.5, 521*, 781.5*, 1042*,MMC0.2* |
4-hour with S9 (2%) | 0*, 65.13, 130.25, 260.5, 521*, 781.5*, 1042*,CP5* |
24-hour without S9 | 0*, 65.13, 130.25, 260.5, 521*, 781.5*, 1042*,DC0.075* |
* = Dose levels selected for analysis of micronucleus frequency in binucleate cells
MMC = MitomycinC
CP = Cyclophosphamide
DC =Demecolcine
Table 1: CBPI - Preliminary Toxicity test
4-hour exposure without S9 |
4-hour exposure with S9 |
24-hour exposure without S9 | |||||||||||||||
Dose Level μg/mL | Nucleate Cells/500 Cells |
CBPI |
% Cytostasis |
Dose Level μg/mL | Nucleate Cells/500 Cells |
CBPI |
% Cytostasis |
Dose Level μg/mL | Nucleate Cells/500 Cells |
CBPI |
% Cytostasis | ||||||
Mono |
Bi |
Multi |
Mono |
Bi |
Multi |
Mono |
Bi |
Multi | |||||||||
0 |
248 |
228 |
24 |
1.55 |
0 |
0 |
229 |
244 |
27 |
1.60 |
0 |
0 |
83 |
313 |
104 |
2.04 |
0 |
4.07 |
- |
- |
- |
- |
- |
4.07 |
- |
- |
- |
- |
- |
4.07 |
- |
- |
- |
- |
- |
8.14 |
- |
- |
- |
- |
- |
8.14 |
- |
- |
- |
- |
- |
8.14 |
- |
- |
- |
- |
- |
16.28 |
- |
- |
- |
- |
- |
16.28 |
- |
- |
- |
- |
- |
16.28 |
- |
- |
- |
- |
- |
32.56 |
- |
- |
- |
- |
- |
32.56 |
- |
- |
- |
- |
- |
32.56 |
- |
- |
- |
- |
- |
65.13 |
- |
- |
- |
- |
- |
65.13 |
- |
- |
- |
- |
- |
65.13 |
- |
- |
- |
- |
- |
130.25 |
- |
- |
- |
- |
- |
130.25 |
- |
- |
- |
- |
- |
130.25 |
- |
- |
- |
- |
- |
260.5 |
244 |
229 |
27 |
1.57 |
0‡ |
260.5 |
270 |
210 |
20 |
1.50 |
17 |
260.5 |
101 |
306 |
93 |
1.98 |
6 |
521 |
296 |
193 |
11 |
1.43 |
22 |
521 |
201 |
282 |
17 |
1.63 |
0‡ |
521 |
54 |
354 |
92 |
2.08 |
0‡ |
1042 |
228 |
255 |
17 |
1.58 |
0‡ |
1042 |
259 |
224 |
17 |
1.52 |
13 |
1042 |
66 |
345 |
89 |
2.05 |
0‡ |
- = Not selected for scoring
‡ = Cytosis reported as 0 as the CBPI value is equal to or higher than the solvent control
Table 2: CBPI Data - Main Experiment - 4HOUR Exposure With and Without Metabolic Activation (S9)
4-Hour exposure without S9 | 4-hour exposure with S9 | ||||||||||||||
Dose level (µg/mL) |
Replicate |
Nucleate cells /500 cells |
CBPI |
Mean CBPI |
% Cytostasis |
Dose level (µg/mL) |
Replicate |
Nucleate cells /500 cells |
CBPI |
Mean CBPI |
% Cytostasis | ||||
M ono | Bi | Multi | M ono | Bi | Multi | ||||||||||
0 | A | 125 | 316 | 59 | 1.87 |
1.89 |
0 |
0 | A | 227 | 241 | 32 | 1.61 |
1.65 |
0 |
B | 109 | 333 | 58 | 1.90 | B | 203 | 251 | 46 | 1.69 | ||||||
65.13 | A | - | - | - | - |
- |
- |
65.13 | A | - | - | - | - |
- |
- |
B | - | - | - | - | B | - | - | - | - | ||||||
130.25 | A | - | - | - | - |
- |
- |
130.25 | A | - | - | - | - |
- |
- |
B | - | - | - | - | B | - | - | - | - | ||||||
260.5 | A | - | - | - | - |
- |
- |
260.5 | A | - | - | - | - |
- |
- |
B | - | - | - | - | B | - | - | - | - | ||||||
521 | A | 150 | 306 | 44 | 1.79 |
1.80 |
10 |
521 | A | 231 | 244 | 25 | 1.59 |
1.59 |
10 |
B | 150 | 302 | 48 | 1.80 | B | 233 | 244 | 23 | 1.58 | ||||||
781.5 | A | 125 | 331 | 44 | 1.84 |
1.84 |
5 |
781.5 | A | 217 | 253 | 30 | 1.63 |
1.59 |
9 |
B | 113 | 353 | 34 | 1.84 | B | 258 | 209 | 33 | 1.55 | ||||||
1042 | A | 144 | 325 | 31 | 1.77 |
1.76 |
15 |
1042 | A | 265 | 209 | 26 | 1.52 |
1.58 |
12 |
B | 172 | 286 | 42 | 1.74 | B | 218 | 247 | 35 | 1.63 | ||||||
MMC 0.2 | A | 268 | 227 | 5 | 1.47 |
1.48 |
46 |
CP 5 | A | 356 | 142 | 2 | 1.29 |
1.31 |
53 |
B | 258 | 238 | 4 | 1.49 | B | 346 | 146 | 8 | 1.32 |
MMC = Mitomycin C
CP = Cyclophosphamide
- = No selected for scoring
Table 3: CBPI Data - Main Experiment - 24-Hour Exposure Without Metabolic Activation (S9)
24-Hour exposure without S9 | |||||||
Dose level (µg/mL) |
Replicate |
Nucleate cells /500 cells |
CBPI |
Mean CBPI |
% Cytostasis | ||
Mono | Bi | Multi | |||||
0 | A | 82 | 383 | 65 | 1.97 |
1.96 |
0 |
B | 96 | 340 | 64 | 1.94 | |||
65.13 | A | - | - | - | - |
- |
- |
B | - | - | - | - | |||
130.25 | A | - | - | - | - |
- |
- |
B | - | - | - | - | |||
260.5 | A | - | - | - | - |
- |
- |
B | - | - | - | - | |||
521 | A | 91 | 346 | 63 | 1.94 |
1.96 |
0‡ |
B | 89 | 336 | 75 | 1.97 | |||
781.5 | A | 75 | 366 | 59 | 1.97 |
1.99 |
0‡ |
B | 74 | 345 | 81 | 2.01 | |||
1042 | A | 69 | 366 | 65 | 1.99 |
1.97 |
0‡ |
B | 88 | 346 | 57 | 1.94 | |||
DC 0.075 | A | 196 | 259 | 45 | 1.70 |
1.66 |
31 |
B | 237 | 218 | 45 | 1.62 |
DC = Demecolcine
- = Not selected for scoring
‡ = Cytosis reported as 0 as the CBPI value is equal to or higher than the solvent control
Table 4: CBPI and Micronucleus Data - Main Experiment - 4-Hour Exposure Without Metabolic Activation (S9)
Exposure Time +/-S9 |
Dose Level (μg/mL) |
Replicate |
Nucleate cells /500 cells |
CBPI |
% Cytostasis | Micronuclei (MN) Per 1000 Binucleate cells | % Binucleate Cells with MN | Mean % Binucleate Cells with MN | ||||
Mono |
Bi |
Multi |
1 MN |
2 MN |
>2 MN | |||||||
4Hr-S9 |
0 | A | 125 | 316 | 59 | 1.87 |
0 | 5 | 0 | 0 | 0.50 |
0.65 |
B | 109 | 333 | 58 | 1.90 | 7 | 1 | 0 | 0.80 | ||||
521 | A | 150 | 306 | 44 | 1.79 |
10 | 3 | 0 | 0 | 0.30 |
0.40 | |
B | 150 | 302 | 48 | 1.80 | 5 | 0 | 0 | 0.50 | ||||
781.5 | A | 125 | 331 | 44 | 1.84 |
5 | 6 | 0 | 0 | 0.60 |
0.50 | |
B | 113 | 353 | 34 | 1.84 | 4 | 0 | 0 | 0.40 | ||||
1042 | A | 144 | 325 | 31 | 1.77 |
15 | 4 | 1 | 0 | 0.50 |
0.45 | |
B | 172 | 286 | 42 | 1.74 | 3 | 1 | 0 | 0.40 | ||||
MMC 0.2 | A | 268 | 227 | 5 | 1.47 |
46 | 62 | 5 | 0 | 6.70 |
9.7*** | |
B | 258 | 238 | 4 | 1.49 | 116 | 8 | 3 | 12.70 |
MMC = Mitomycin C
*** = P<0.001
Table 5: CBPI and Micronucleus Data - Experiment - 4-Hour Exposure With Metabolic Activation (S9)
Exposure Time +/-S9 |
Dose Level (μg/mL) |
Replicate |
Nucleate cells /500 cells |
CBPI |
% Cytostasis | Micronuclei (MN) Per 1000 Binucleate cells | % Binucleate Cells with MN | Mean % Binucleate Cells with MN | ||||
Mono |
Bi |
Multi |
1 MN |
2 MN |
>2 MN | |||||||
4Hr+S9 |
0 | A | 227 | 241 | 32 | 1.61 |
0 | 5 | 0 | 0 | 0.50 |
0.45 |
B | 203 | 251 | 46 | 1.69 | 4 | 0 | 0 | 0.40 | ||||
521 | A | 231 | 244 | 25 | 1.59 |
10 | 1 | 1 | 0 | 0.20 |
0.25 | |
B | 233 | 244 | 23 | 1.58 | 3 | 0 | 0 | 0.30 | ||||
781.5 | A | 217 | 253 | 30 | 1.63 |
9 | 5 | 1 | 1 | 0.70 |
0.55 | |
B | 258 | 209 | 33 | 1.55 | 4 | 0 | 0 | 0.40 | ||||
1042 | A | 265 | 209 | 26 | 1.52 |
12 | 4 | 0 | 0 | 0.40 |
0.50 | |
B | 218 | 247 | 35 | 1.63 | 6 | 0 | 0 | 0.60 | ||||
CP 5 | A | 356 | 142 | 2 | 1.29 |
53 | 35 | 2 | 0 | 3.70 |
4.15*** | |
B | 346 | 146 | 8 | 1.32 | 44 | 2 | 0 | 4.60 |
CP = Cyclophosphamide
*** = P<0.001
Table 6: CBPI and Micronucleus Data - Main Experiment - 24-Hour Exposure Without Metabolic Activation (S9)
Exposure Time +/- S9 |
Dose Level (μg/mL) |
Replicate |
Nucleate cells /500 cells |
CBPI |
% Cytostasis | Micronuclei (MN) Per 1000 Binucleate cells | % Binucleate Cells with MN | Mean % Binucleate Cells with MN | ||||
Mono |
Bi |
Multi |
1 MN |
2 MN |
>2 MN | |||||||
24Hr-S9 |
0 | A | 82 | 383 | 65 | 1.97 |
0 | 6 | 0 | 1 | 0.70 |
0.55 |
B | 96 | 340 | 64 | 1.94 | 3 | 0 | 1 | 0.40 | ||||
521 | A | 91 | 346 | 63 | 1.94 |
0‡ | 5 | 0 | 0 | 0.50 |
0.65 | |
B | 89 | 336 | 75 | 1.97 | 6 | 0 | 2 | 0.80 | ||||
781.5 | A | 75 | 366 | 59 | 1.97 |
0‡ | 7 | 0 | 0 | 0.70 |
0.90 | |
B | 74 | 345 | 81 | 2.01 | 11 | 0 | 0 | 1.10 | ||||
1042 | A | 69 | 366 | 65 | 1.99 |
0‡ | 0 | 0 | 0 | 0.00 |
0.40 | |
B | 88 | 346 | 57 | 1.94 | 2 | 0 | 6 | 0.80 | ||||
DC 0.075 | A | 196 | 259 | 45 | 1.70 |
31 | 40 | 9 | 5 | 5.40 |
5.75*** | |
B | 237 | 218 | 45 | 1.62 | 36 | 19 | 6 | 6.10 |
DC = Demecolcine
*** = P<0.001
‡ = Cytosis reported as 0 as the CBPI value is equal to or higher than the solvent control
Table 1 Summary of Results
Experiment 1
Treatment (µg/mL) |
4-hours-S-9 |
Treatment (µg/mL) |
4-hours+S-9 |
||||
%RSG |
RTG |
MF§ |
%RSG |
RTG |
MF§ |
||
0 |
100 |
1.00 |
134.37 |
0 |
100 |
1.00 |
133.60 |
32.56 |
104 |
1.10 |
121.22 |
32.56 |
95 |
1.01 |
104.40 |
65.13 |
111 |
1.17 |
132.84 |
65.13 |
97 |
0.94 |
143.60 |
130.25 |
101 |
0.95 |
134.50 |
130.25 |
88 |
0.86 |
133.35 |
260.5 |
100 |
1.03 |
133.06 |
260.5 |
92 |
1.05 |
124.08 |
521 |
99 |
1.03 |
153.20 |
521 |
96 |
0.89 |
131.38 |
1042 |
101 |
1.06 |
128.94 |
1042 |
83 |
0.76 |
164.02 |
MF threshold for a positive response=260.37 |
MF threshold for a positive response=256.60 |
||||||
EMS |
66 |
0.45 |
1637.45 |
CP |
62 |
0.38 |
831.08 |
400 |
1.5 |
Treatment (µg/mL) |
24-hours-S-9 |
||
%RSG |
RTG |
MF§ |
|
0 |
100 |
1.00 |
133.14 |
32.56 |
99 |
1.02 |
137.78 |
65.13 |
81 |
0.94 |
107.17 |
130.25 |
95 |
0.99 |
138.96 |
260.5 |
96 |
1.05 |
157.24 |
521 |
95 |
1.00 |
144.90 |
1042 |
66 |
0.83 |
158.52 |
MF threshold for a positive response=259.14 |
|||
EMS |
38 |
0.36 |
1707.56 |
150 |
Table 2 Cell and 96-Well Plate Counts: Mutagenicity Test (-S9) 4-Hour Exposure
Treatment (µg/mL) |
Cell counts $ |
Viability § after day 2 2 cells/well |
Resistant mutants § after day 2 2000 cells/well |
|||||||||
0h |
24h |
48h |
||||||||||
0 |
A B |
8.07 8.01 |
7.36 7.26 |
6.37 6.20 |
72 77 |
75 74 |
76 81 |
72 83 |
12 20 |
20 18 |
16 20 |
15 26 |
32.56 |
A B |
7.66 7.27 |
7.20 7.75 |
6.81 6.96 |
78 80 |
80 73 |
|
|
17 16 |
16 21 |
|
|
65.13 |
A B |
8.16 8.19 |
7.13 7.29 |
7.03 6.88 |
77 77 |
77 80 |
|
|
19 18 |
18 21 |
|
|
130.25 |
A B |
7.39 7.42 |
7.70 7.02 |
6.58 7.06 |
72 78 |
75 73 |
|
|
16 17 |
20 17 |
|
|
260.5 |
A B |
7.30 6.50 |
7.55 7.95 |
7.03 6.75 |
80 75 |
75 79 |
|
|
17 19 |
21 18 |
|
|
521 |
A B |
7.90 7.34 |
7.28 7.36 |
6.87 6.29 |
76 79 |
76 78 |
|
|
18 23 |
20 24 |
|
|
1042 |
A B |
7.57 6.55 |
7.22 8.16 |
7.58 6.19 |
78 73 |
79 81 |
|
|
18 22 |
16 18 |
|
|
Positive Control EMS (µg/mL) |
||||||||||||
400 |
A B |
7.03 7.06 |
5.86 5.09 |
6.03 6.64 |
70 67 |
62 54 |
|
|
92 73 |
76 77 |
|
|
Table 3 Summary Analysis: Mutagenicity Test (-S9) 4-Hour Exposure
Treatment (µg/mL) |
SG |
%RSG |
%V |
RTG |
MF§ |
0 |
11.49 |
100 |
79.06 |
1.00 |
134.37 |
32.56 |
12.87 |
104 |
83.01 |
1.10 |
121.22 |
65.13 |
12.54 |
111 |
83.01 |
1.17 |
132.84 |
130.25 |
12.55 |
101 |
74.81 |
0.95 |
134.50 |
260.5 |
13.35 |
100 |
81.66 |
1.03 |
133.06 |
521 |
12.04 |
99 |
81.66 |
1.03 |
153.20 |
1042 |
13.24 |
101 |
83.01 |
1.06 |
128.94 |
Positive Control EMS |
|||||
Treatment (µg/mL) |
SG |
%RSG |
%V |
RTG |
MF§ |
400 |
8.67 |
66 |
53.77 |
0.45 |
1637.45 |
GEF =126, therefore MF threshold for a positive response = 260.37
Table 4 Large and Small Colonies Analysis: Mutagenicity Test (-S9) 4-Hour Exposure
Treatment (µg/mL) |
Viability # after day 2 |
Small colonies # after day 2 |
Large colonies # after day 2 |
||||||||||
0 |
A B |
72 77 |
75 74 |
76 81 |
72 83 |
5 11 |
9 8 |
7 7 |
10 12 |
7 9 |
11 10 |
9 13 |
5 14 |
32.56 |
A B |
78 80 |
80 73 |
|
|
9 10 |
6 10 |
|
|
8 6 |
10 11 |
|
|
65.13 |
A B |
77 77 |
77 80 |
|
|
14 9 |
5 7 |
|
|
5 9 |
13 14 |
|
|
130.25 |
A B |
72 78 |
75 73 |
|
|
9 7 |
8 10 |
|
|
7 10 |
12 7 |
|
|
260.5 |
A B |
80 75 |
75 79 |
|
|
7 6 |
9 9 |
|
|
10 13 |
12 9 |
|
|
521 |
A B |
76 79 |
76 78 |
|
|
9 9 |
9 10 |
|
|
9 14 |
11 14 |
|
|
1042 |
A B |
78 73 |
79 81 |
|
|
8 8 |
7 11 |
|
|
10 14 |
9 7 |
|
|
400 EMS |
A B |
70 67 |
62 54 |
|
|
44 38 |
38 38 |
|
|
48 35 |
38 39 |
|
|
Mutation frequencies
Treatment (µg/mL) |
|
Small colonies |
Large Colonies |
Proportion small colony mutants |
|||||
Viable |
Mutants |
MF§ |
Mutants |
MF§ |
|||||
Yv |
Nv |
Ym |
Nm |
Ym |
Nm |
||||
0 |
158 |
768 |
699 |
768 |
59.5 |
690 |
768 |
67.7 |
0.47 |
32.56 |
73 |
384 |
349 |
384 |
57.6 |
349 |
384 |
57.6 |
0.50 |
65.13 |
73 |
384 |
349 |
384 |
57.6 |
343 |
384 |
68.0 |
0.46 |
130.25 |
86 |
384 |
350 |
384 |
62.0 |
348 |
384 |
65.8 |
0.49 |
260.5 |
75 |
384 |
353 |
384 |
51.5 |
340 |
384 |
74.5 |
0.41 |
521 |
75 |
384 |
347 |
384 |
62.0 |
336 |
384 |
81.8 |
0.44 |
1042 |
73 |
384 |
350 |
384 |
55.8 |
344 |
384 |
66.3 |
0.46 |
400 EMS |
131 |
384 |
116 |
384 |
1113.1 |
118 |
384 |
1097.2 |
0.50 |
Table 5 Cell and 96-Well Plate Counts: Mutagenicity Test (+S9) 4-Hour Exposure
Treatment (µg/mL) |
Cell counts $ |
Viability § after day 2 2 cells/well |
Resistant mutants § after day 2 2000 cells/well |
|||||||||
0h |
24h |
48h |
||||||||||
0 |
A B |
6.89 7.64 |
7.78 7.64 |
8.96 7.78 |
72 80 |
69 80 |
78 82 |
76 80 |
17 20 |
21 17 |
15 23 |
17 20 |
32.56 |
A B |
6.82 7.51 |
8.37 8.02 |
8.03 7.22 |
79 86 |
76 74 |
|
|
18 11 |
18 16 |
|
|
65.13 |
A B |
7.37 6.32 |
7.90 9.12 |
7.33 8.29 |
78 80 |
75 72 |
|
|
19 19 |
21 19 |
|
|
130.25 |
A B |
7.12 6.67 |
7.44 8.65 |
7.39 7.54 |
71 79 |
82 73 |
|
|
15 19 |
20 19 |
|
|
260.5 |
A B |
7.57 6.90 |
8.15 7.41 |
8.07 7.19 |
82 76 |
85 81 |
|
|
20 20 |
17 22 |
|
|
521 |
A B |
7.54 6.72 |
6.44 7.60 |
9.42 8.51 |
75 77 |
79 70 |
|
|
15 17 |
19 19 |
|
|
1042 |
A B |
6.59 7.06 |
7.56 7.19 |
7.63 7.86 |
71 78 |
75 73 |
|
|
18 21 |
24 20 |
|
|
Positive Control CP (µg/mL) |
||||||||||||
1.5 |
A B |
6.81 6.00 |
6.56 7.05 |
6.85 6.52 |
62 66 |
58 57 |
|
|
58 50 |
49 60 |
|
|
Table 6 Summary Analysis: Mutagenicity Test (+S9) 4-Hour Exposure
Treatment (µg/mL) |
SG |
%RSG |
%V |
RTG |
MF§ |
0 |
16.13 |
100 |
81.33 |
1.00 |
133.60 |
32.56 |
15.62 |
95 |
85.83 |
1.01 |
104.40 |
65.13 |
16.62 |
97 |
79.06 |
0.94 |
143.60 |
130.25 |
15.01 |
88 |
79.06 |
0.86 |
133.35 |
260.5 |
14.8 |
92 |
92.81 |
1.05 |
124.08 |
521 |
15.73 |
96 |
76.59 |
0.89 |
131.38 |
1042 |
14.28 |
83 |
74.24 |
0.76 |
164.02 |
Positive Control CP |
|||||
Treatment (µg/mL) |
SG |
%RSG |
%V |
RTG |
MF§ |
1.5 |
11.37 |
62 |
50.09 |
0.38 |
831.08 |
GEF =126, therefore MF threshold for a positive response = 259.60
Table 7 Large and Small Colonies Analysis: Mutagenicity Test (+S9) 4-Hour Exposure
Treatment (µg/mL) |
Viability # after day 2 |
Small colonies # after day 2 |
Large colonies # after day 2 |
||||||||||
0 |
A B |
72 80 |
69 80 |
78 82 |
76 80 |
9 12 |
8 9 |
8 12 |
8 11 |
8 8 |
13 8 |
7 11 |
9 9 |
32.56 |
A B |
79 86 |
76 74 |
|
|
13 1 |
6 7 |
|
|
5 10 |
12 9 |
|
|
65.13 |
A B |
78 80 |
75 72 |
|
|
9 10 |
9 7 |
|
|
10 9 |
12 12 |
|
|
130.25 |
A B |
71 79 |
82 73 |
|
|
9 9 |
5 4 |
|
|
6 10 |
15 15 |
|
|
260.5 |
A B |
82 76 |
85 81 |
|
|
12 7 |
9 9 |
|
|
8 13 |
8 13 |
|
|
521 |
A B |
75 77 |
79 70 |
|
|
10 4 |
6 7 |
|
|
5 13 |
13 12 |
|
|
1042 |
A B |
71 78 |
75 73 |
|
|
10 10 |
10 10 |
|
|
8 11 |
14 10 |
|
|
1.5 CP |
A B |
62 66 |
58 57 |
|
|
37 28 |
38 33 |
|
|
21 22 |
11 27 |
|
|
Mutation frequencies
Treatment (µg/mL) |
|
Small colonies |
Large Colonies |
Proportion small colony mutants |
|||||
Viable |
Mutants |
MF§ |
Mutants |
MF§ |
|||||
Yv |
Nv |
Ym |
Nm |
Ym |
Nm |
||||
0 |
151 |
768 |
691 |
768 |
65.0 |
695 |
768 |
61.4 |
0.51 |
32.56 |
69 |
384 |
357 |
384 |
42.5 |
348 |
384 |
57.3 |
0.43 |
65.13 |
79 |
384 |
349 |
384 |
60.4 |
341 |
384 |
75.1 |
0.45 |
130.25 |
79 |
384 |
357 |
384 |
46.1 |
338 |
384 |
80.7 |
0.37 |
260.5 |
60 |
384 |
347 |
384 |
54.6 |
342 |
384 |
62.4 |
0.47 |
521 |
83 |
384 |
357 |
384 |
47.6 |
341 |
384 |
77.5 |
0.39 |
1042 |
87 |
384 |
344 |
384 |
74.1 |
341 |
384 |
80.0 |
0.48 |
1.5 CP |
141 |
384 |
248 |
384 |
436.4 |
303 |
384 |
236.5 |
0.63 |
Table 8 Cell and 96-Well Plate Counts: Mutagenicity Test (-S9) 24-Hour Exposure
Treatment (µg/mL) |
Cell counts $ |
Viability § after day 2 2 cells/well |
Resistant mutants § after day 2 2000 cells/well |
|||||||||
0h |
24h |
48h |
||||||||||
0 |
A B |
9.64 9.62 |
6.68 6.96 |
7.79 8.73 |
81 80 |
76 78 |
83 82 |
81 79 |
24 21 |
21 23 |
19 17 |
19 19 |
32.56 |
A B |
9.68 9.10 |
6.67 6.59 |
8.58 9.18 |
86 75 |
78 81 |
|
|
23 23 |
17 21 |
|
|
65.13 |
A B |
8.60 8.96 |
7.28 6.14 |
7.62 8.81 |
84 81 |
80 82 |
|
|
15 19 |
16 21 |
|
|
130.25 |
A B |
10.17 9.24 |
6.45 6.31 |
7.81 8.77 |
78 82 |
82 83 |
|
|
23 21 |
24 20 |
|
|
260.5 |
A B |
9.02 8.84 |
6.67 7.38 |
8.18 9.71 |
85 76 |
82 78 |
|
|
21 26 |
26 22 |
|
|
521 |
A B |
9.31 9.93 |
6.74 6.05 |
7.74 9.11 |
77 84 |
79 86 |
|
|
26 25 |
17 24 |
|
|
1042 |
A B |
8.02 8.72 |
6.79 5.77 |
8.29 7.45 |
77 85 |
80 86 |
|
|
24 26 |
25 26 |
|
|
Positive Control EMS (µg/mL) |
||||||||||||
150 |
A B |
6.39 7.21 |
5.68 5.51 |
7.83 7.56 |
66 73 |
61 69 |
|
|
83 89 |
79 84 |
|
|
Table 9 Summary Analysis: Mutagenicity Test (-S9) 24-Hour Exposure
Treatment (µg/mL) |
SG |
%RSG |
%V |
RTG |
MF§ |
0 |
90.41 |
100 |
89.59 |
1.00 |
133.14 |
32.56 |
92.14 |
99 |
89.59 |
1.02 |
137.78 |
65.13 |
80.66 |
81 |
95.38 |
0.94 |
107.17 |
130.25 |
85.55 |
95 |
93.66 |
0.99 |
138.96 |
260.5 |
93.52 |
96 |
90.38 |
1.05 |
157.24 |
521 |
86.38 |
95 |
94.51 |
1.00 |
144.90 |
1042 |
68.95 |
66 |
96.26 |
0.83 |
158.52 |
Positive Control EMS (µg/mL) |
|||||
Treatment (µg/mL) |
SG |
%RSG |
%V |
RTG |
MF§ |
150 |
48.79 |
38 |
60.29 |
0.36 |
1707.56 |
GEF =126, therefore MF threshold for a positive response = 259.14
Table 10 Large and Small Colonies Analysis: Mutagenicity Test (-S9) 24-Hour Exposure
Treatment
(µg/mL) |
Viability # after day 2 |
Small colonies # after day 2 |
Large colonies # after day 2 |
||||||||||
0 |
A B |
81 80 |
76 78 |
83 82 |
81 79 |
9 16 |
12 7 |
8 5 |
7 11 |
15 5 |
9 16 |
11 12 |
12 8 |
32.56 |
A B |
86 75 |
78 81 |
|
|
10 11 |
10 12 |
|
|
13 12 |
7 9 |
|
|
65.13 |
A B |
84 81 |
80 82 |
|
|
6 8 |
10 12 |
|
|
9 11 |
6 9 |
|
|
130.25 |
A B |
78 82 |
82 83 |
|
|
15 12 |
9 11 |
|
|
8 9 |
15 9 |
|
|
260.5 |
A B |
85 76 |
82 78 |
|
|
13 13 |
11 16 |
|
|
8 13 |
15 6 |
|
|
521 |
A B |
77 84 |
79 86 |
|
|
13 13 |
8 10 |
|
|
13 12 |
9 14 |
|
|
1042 |
A B |
77 85 |
80 86 |
|
|
16 12 |
9 11 |
|
|
8 14 |
16 15 |
|
|
150 EMS |
A B |
66 73 |
61 69 |
|
|
47 48 |
43 48 |
|
|
36 41 |
36 36 |
|
|
Mutation frequencies
Treatment (µg/mL) |
|
Small colonies |
Large Colonies |
Proportion small colony mutants |
|||||
Viable |
Mutants |
MF§ |
Mutants |
MF§ |
|||||
Yv |
Nv |
Ym |
Nm |
Ym |
Nm |
||||
0 |
128 |
768 |
693 |
768 |
57.4 |
680 |
768 |
67.9 |
0.46 |
32.56 |
64 |
384 |
341 |
384 |
66.3 |
343 |
384 |
63.0 |
0.51 |
65.13 |
57 |
384 |
348 |
384 |
51.6 |
349 |
384 |
50.1 |
0.51 |
130.25 |
59 |
384 |
337 |
384 |
69.7 |
343 |
384 |
60.3 |
0.53 |
260.5 |
63 |
384 |
331 |
384 |
82.2 |
342 |
384 |
64.1 |
0.56 |
521 |
58 |
384 |
340 |
384 |
64.4 |
336 |
384 |
70.6 |
0.48 |
1042 |
56 |
384 |
336 |
384 |
69.4 |
331 |
384 |
77.1 |
0.48 |
150 EMS |
115 |
384 |
198 |
384 |
549.4 |
235 |
384 |
407.3 |
0.56 |
KEY TO TABLES 1 TO 10
$ |
= |
Cell counts (x10e5cells/mL). Set up on previous day to 2 x 10e5cells/mL unless otherwise stated in parenthesis. |
|
|
|
%RSG |
= |
Relative Suspension Growth |
RTG |
= |
Relative Total Growth |
%V |
= |
Viability Day 2 |
§ or # |
= |
Positive wells per tray, 96 wells plated unless otherwise stated in parenthesis |
A,B |
= |
Replicate cultures |
CP |
= |
Cyclophosphamide |
EMS |
= |
Ethylmethanesulphonate |
MF§ |
= |
5-TFT resistant mutants/10e6 viable cells 2 days after exposure |
Nv |
= |
Number of wells scored, viability plates |
Yv |
= |
Number of wells without colonies, viability plates |
Ym |
= |
Number of wells without colonies, mutation plates |
Nm |
= |
Number of wells scored, mutation plates |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Description of key information
As stated in Annex IX of REACH Regulation (column 2, point 8.4), in absence of positive results in any of the in vitro genotoxicity studies in Annex VII or VIII and in absence of results available from an in vivo study already, in vivo somatic cell genotoxicity study are not required.
Three reliable in vitro genetic toxicity studies were performed on Diethoxymethane (gene mutation in bacteria, micronucleus test in vitro and mouse lymphoma assay (tk+/- locus)) and gave negative results. In vivo study are consequently not required.
Additional information
Justification for classification or non-classification
The substance was found to be negative for mutagenicity in both the ames test and in vitro micronucleus test, and was therefore not classified for this endpoint.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.